TD Cowen Forecasts Strong Price Appreciation for Natera (NASDAQ:NTRA) Stock

Natera (NASDAQ:NTRA) had its target price increased by equities research analysts at TD Cowen from $155.00 to $175.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. TD Cowen’s price target would suggest a potential upside of 5.75% from the company’s current price.

A number of other brokerages have also recently commented on NTRA. Piper Sandler reiterated an “overweight” rating and issued a $150.00 price target on shares of Natera in a research note on Friday, September 13th. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Leerink Partners increased their price objective on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Canaccord Genuity Group raised their price target on shares of Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Sanford C. Bernstein raised their price target on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $135.06.

Natera Stock Up 22.5 %

Shares of NTRA stock traded up $30.37 during trading on Wednesday, reaching $165.49. The company’s stock had a trading volume of 2,689,452 shares, compared to its average volume of 1,319,496. Natera has a one year low of $49.97 and a one year high of $167.79. The business has a fifty day moving average price of $125.09 and a 200-day moving average price of $114.52. The company has a market cap of $20.47 billion, a price-to-earnings ratio of -94.03 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.88%. The company’s revenue for the quarter was up 63.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.95) EPS. Analysts anticipate that Natera will post -1.96 earnings per share for the current year.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 256 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total value of $30,737.92. Following the completion of the sale, the insider now directly owns 111,891 shares in the company, valued at $13,434,752.37. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In other Natera news, insider Solomon Moshkevich sold 256 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the transaction, the insider now owns 111,891 shares in the company, valued at approximately $13,434,752.37. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Sheena sold 12,000 shares of the stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the transaction, the insider now directly owns 287,441 shares in the company, valued at $34,783,235.41. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,464 shares of company stock worth $5,849,977. 7.60% of the stock is currently owned by insiders.

Institutional Trading of Natera

Several hedge funds have recently bought and sold shares of the stock. Itau Unibanco Holding S.A. bought a new position in shares of Natera during the 2nd quarter valued at approximately $28,000. Quarry LP boosted its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC raised its position in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the period. Covestor Ltd lifted its stake in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares in the last quarter. Finally, Brooklyn Investment Group bought a new position in shares of Natera in the 3rd quarter valued at about $70,000. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.